Raymond Woo Sells 11,112 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 11,112 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $18.56, for a total value of $206,238.72. Following the completion of the sale, the chief technology officer owned 166,912 shares of the company’s stock, valued at $3,097,886.72. This represents a 6.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raymond Woo also recently made the following trade(s):

• On Monday, March 2nd, Raymond Woo sold 8,087 shares of CeriBell stock. The stock was sold at an average price of $18.25, for a total value of $147,587.75.
• On Monday, February 23rd, Raymond Woo sold 705 shares of CeriBell stock. The shares were sold at an average price of $19.79, for a total value of $13,951.95.

CeriBell Stock Performance

Shares of NASDAQ:CBLL opened at $18.57 on Friday. The firm’s 50 day simple moving average is $19.31 and its 200 day simple moving average is $17.45. CeriBell, Inc. has a fifty-two week low of $10.01 and a fifty-two week high of $24.33. The company has a market capitalization of $698.97 million, a price-to-earnings ratio of -12.63 and a beta of 0.94. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.73 and a quick ratio of 9.35.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. The firm had revenue of $24.78 million during the quarter, compared to analysts’ expectations of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. As a group, sell-side analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on CBLL. TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. BTIG Research restated a “buy” rating and issued a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. Finally, Canaccord Genuity Group raised their price target on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.20.

Institutional Investors Weigh In On CeriBell

A number of hedge funds and other institutional investors have recently made changes to their positions in CBLL. Russell Investments Group Ltd. lifted its position in CeriBell by 41.4% in the 4th quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock valued at $64,000 after acquiring an additional 854 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after purchasing an additional 1,231 shares in the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of CeriBell by 97.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after purchasing an additional 1,256 shares during the period. Deutsche Bank AG lifted its holdings in shares of CeriBell by 1.7% in the fourth quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after purchasing an additional 1,393 shares in the last quarter. Finally, Royal Bank of Canada boosted its position in shares of CeriBell by 10.8% during the fourth quarter. Royal Bank of Canada now owns 15,588 shares of the company’s stock worth $342,000 after buying an additional 1,514 shares during the period.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.